[
1. Horacek J, Bubenikova-Valesova V, Kopecek M, Palenicek T, Dockery C, Mohr P, et al. Mechanism of action of atypical antipsychotic drugs and the neurobiology of schizophrenia. CNS Drugs. 2006;20:389-409.10.2165/00023210-200620050-00004
]Search in Google Scholar
[
2. Gex-Fabry M, Balant-Gorgia AE, Balant LP. Therapeutic drug monitoring of olanzapine: the combined effect of age, gender, smoking, and comedication. Ther Drug Monit. 2003;25:46-53.10.1097/00007691-200302000-00007
]Search in Google Scholar
[
3. Kapur S, Zipursky RB, Remington G, Jones C, DaSilva J, Wilson AA, et al. 5-HT2 and D2 receptor occupancy of olanzapine in schizophrenia: a PET investigation. Am J Psychiatry. 1998;155:921-8.10.1176/ajp.155.7.921
]Search in Google Scholar
[
4. Kassahun K, Mattiuz E, Nyhart E Jr, Obermeyer B, Gillespie T, Murphy A, et al. Disposition and biotrans-formation of the antipsychotic agent olanzapine in humans. Drug Metab Dispos. 1997;25: 81-93.
]Search in Google Scholar
[
5. Kelleher JP, Centorrino F, Albert MJ, Baldessarini RJ. Advances in atypical antipsychotics for the treatment of schizophrenia: new formulations and new agents. CNS Drugs. 2002;16:249-61.10.2165/00023210-200216040-00004
]Search in Google Scholar
[
6. Kelly DL, Conley RR, Tamminga CA. Differential olanzapine plasma concentrations by sex in a fixeddose study. Schizophr Res. 1999;40:101-14.10.1016/S0920-9964(99)00053-5
]Search in Google Scholar
[
7. McCormack PL, Wiseman LR. Olanzapine: a review of its use in the management of bipolar disorder. Drugs. 2004;64:2709-26.10.2165/00003495-200464230-00006
]Search in Google Scholar
[
8. Miyamoto S, Duncan GE, Marx CE, Lieberman JA. Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs. Molecular Psychiatry. 2005;10:79–104.10.1038/sj.mp.4001556
]Search in Google Scholar
[
9. Stockton ME, Rasmussen K. Electrophysiological effects of olanzapine, a novel atypical antipsychotic, on A9 and A10 dopamine neurons. Neuropsychopharmacology.1996;14:97-104.10.1016/0893-133X(94)00130-R
]Search in Google Scholar
[
10. D. Vancampfort, K. Vansteelandt, C.U. Correll, A.J. Mitchell, A. De Herdt, P. Sienaert, M. Probst, M. De Hert, Metabolic syndrome and metabolic abnormalities in bipolar disorder: a meta-analysis of prevalence rates and moderators, Am. J. Psychiatry 170 (2013) 265–274.
]Search in Google Scholar
[
11. F.C. Cohen, Entry order as a consideration for innovation strategies, Nat. Rev.Durg Discovery (2006).10.1038/nrd200916531989
]Search in Google Scholar
[
12. M. Leonhauser, 2012. Antisychotics: multiple indications help drive growth. Pm 360 marjet watch: the essential source for pharma marketers, 1, 22–24.
]Search in Google Scholar
[
13. Davis H, Attia E. Pharmacotherapy of eating disorders. Curr Opin Psychiatry. 2017; doi: 10.1097/YCO.0000000000000358.10.1097/YCO.0000000000000358822140428806268
]Search in Google Scholar
[
14. Lord CC, Wyler SC, Wan R, Castorena CM, Ahmed N, Mathew D, Lee S, Liu C, Elmquist JK. The atypical antipsychotic olanzapine causes weight gain by targeting serotonin receptor 2C. J Clin Invest. 2017. pii: 93362. doi: 10.1172/JCI93362.10.1172/JCI93362
]Search in Google Scholar
[
15. Bymaster FP, et al. Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology. 1996;14(2):87–96.10.1016/0893-133X(94)00129-N
]Search in Google Scholar
[
16. Meltzer HY, Huang M. In vivo actions of atypical anti-psychotic drug on serotonergic and dopaminergic systems. Prog Brain Res. 2008;172:177–197.10.1016/S0079-6123(08)00909-6
]Search in Google Scholar
[
17. Kim SF, Huang AS, Snowman AM, Teuscher C, Snyder SH. From the Cover: Antipsychotic drug-induced weight gain mediated by histamine H1 receptor-linked activation of hypothalamic AMP-kinase. Proc Natl Acad Sci U S A. 2007;104(9):3456–3459.10.1073/pnas.0611417104
]Search in Google Scholar
[
18. Bymaster FP, et al. Antagonism by olanzapine of dopamine D1, serotonin2, muscarinic, histamine H1 and alpha 1-adrenergic receptors in vitro. Schizophr Res. 1999;37(1):107–122.10.1016/S0920-9964(98)00146-7
]Search in Google Scholar
[
19. Cooper GD, Pickavance LC, Wilding JP, Harrold JA, Halford JC, Goudie AJ. Effects of olanzapine in male rats: enhanced adiposity in the absence of hyperphagia, weight gain or metabolic abnormalities. J Psychopharmacol. 2007;21(4):405–413.10.1177/026988110606963717050655
]Search in Google Scholar
[
20. Lett TA, Wallace TJ, Chowdhury NI, Tiwari AK, Kennedy JL, Müller DJ. Pharmacogenetics of antipsychotic-induced weight gain: review and clinical implications. Mol Psychiatry. 2012;17(3):242–266.10.1038/mp.2011.10921894153
]Search in Google Scholar
[
21. Fang F, Wang Z, Wu R, Calabrese JR, Gao K. Is there a ‘weight neutral’ second-generation antipsychotic for bipolar disorder? Expert Rev Neurother. 2017;17(4):407-418.10.1080/14737175.2016.127628428005435
]Search in Google Scholar
[
22. Rojo LE, Gaspar PA, Silva H, Risco L, Arena P, Cubillos-Robles K, Jara B. Metabolic syndrome and obesity among users of second generation antipsychotics: A global challenge for modern psychopharmacology. Pharmacol Res. 2015;101:74-85.10.1016/j.phrs.2015.07.02226218604
]Search in Google Scholar
[
23. Himmerich H, Minkwitz J, Kirkby KC. Weight Gain and Metabolic Changes During Treatment with Antipsychotics and Antidepressants. Endocr Metab Immune Disord Drug Targets. 2015;15(4):252-60.10.2174/187153031566615062309203126100432
]Search in Google Scholar
[
24. Datta SS, Kumar A, Wright SD, Furtado VA, Russell PS. Evidence base for using atypical antipsychotics for psychosis in adolescents. Schizophr Bull. 2014;40(2):252-4.10.1093/schbul/sbt196393209224361758
]Search in Google Scholar
[
25. Bartoli F, Lax A, Crocamo C, Clerici M, Carrà G. Plasma adiponectin levels in schizophrenia and role of second-generation antipsychotics: a meta-analysis. Psychoneuroendocrinology. 2015;56:179-89.10.1016/j.psyneuen.2015.03.01225827962
]Search in Google Scholar
[
26. Hirsch L, Yang J, Bresee L, Jette N, Patten S, Pringsheim T. Second-Generation Antipsychotics and Metabolic Side Effects: A Systematic Review of Population-Based Studies. Drug Saf. 2017; doi: 10.1007/s40264-017-0543-0.10.1007/s40264-017-0543-028585153
]Search in Google Scholar
[
27. Allison D, Mentore J, Heo M, Chandler L, Cappelleri J, Infante M, et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry. 1999;156(11):1686–96.10.1176/ajp.156.11.1686
]Search in Google Scholar
[
28. RummelKluge C, Komossa K, Schwarz S, Hunger H, Schmid F, Lobos C, et al. Head-to-head comparisons of metabolic side effects of second generation antipsychotisc in the treatment of schizophrenia: a systematic review and meta analysis. Schizophr Res. 2010;123(2–3):225–33.10.1016/j.schres.2010.07.012295751020692814
]Search in Google Scholar
[
29. Fuller M, Shermock K, Secic M, Grogg A. Comparative study of the development of type 2 diabetes in patients taking risperidone and olanzapine. Pharmacotherapy. 2003;23(8):1037–43.10.1592/phco.23.8.1037.3287612921249
]Search in Google Scholar
[
30. Kessing LV, Thomsen AF, Mogensen UB, Andersen M. Treatment with antipsychotics and the risk of diabetes in clinical practice. Br J Psychiatry. 2010;197(4):266–71.10.1192/bjp.bp.109.07693520884948
]Search in Google Scholar
[
31. Werner FM, Covenas R. Safety of antipsychotic drugs: focus on therapeutic and adverse effects. Expert Opin Drug Saf. 2014;13(8):1031–42.10.1517/14740338.2014.93576124975932
]Search in Google Scholar
[
32. Potkin SG, Phiri P, Szegedi A, et al. Long-term effects of asenapine or olanzapine in patients with persistent negative symptoms of schizophrenia: a pooled analysis. Schizophr Res.2013;150(2–3):442–9.10.1016/j.schres.2013.08.02424075603
]Search in Google Scholar
[
33. Lehman AF, Lieberman JA, Dixon LB, et al. American Psychiatric Association practice guideline for the treatment of patients with schizophrenia, 2nd edn. 2004. http://psychiatryonline.org. Accessed 17 Aug 2017.
]Search in Google Scholar
[
34. Lauriello J, Lambert T, Andersen S, et al. An 8-week, doubleblind, randomized, placebo-controlled study of olanzapine longacting injection in acutely ill patients with schizophrenia. J Clin Psychiatry. 2008;69:790-799.10.4088/JCP.v69n051218452346
]Search in Google Scholar
[
35. Dixon L, Perkins D, Calmes C. American Psychiatric Association guideline watch (September 2009): practice guideline for the treatment of patients with schizophrenia. 2009. http://psychiatryonline.org. Accessed 17 Aug 2017.10.1176/appi.books.9780890423929
]Search in Google Scholar
[
36. De Hert M, Guiraud-Diawara A, Marre C. Comparison of metabolic syndrome incidence among schizophrenia patients treated with asenapine versus olanzapine [abstract no. 2584]. Eur Psychiatry. 2013;28(Suppl 1).10.1016/S0924-9338(13)77249-3
]Search in Google Scholar
[
37. Simpson GM, Weiden P, Pigott T, et al. Six-month, blinded, multicenter continuation study of ziprasidone versus olanzapine in schizophrenia. Am J Psychiatry. 2005;162:1535-1538.10.1176/appi.ajp.162.8.153516055779
]Search in Google Scholar
[
38. Zhang Q, Deng C, Huang XF. The role of ghrelin signalling in second-generation antipsychotic-induced weight gain. Psychoneuroendocrinology. 2013;38(11):2423-38.10.1016/j.psyneuen.2013.07.01023953928
]Search in Google Scholar
[
39. Aguilar E, Coronas R, Caixàs A. [Metabolic syndrome in patients with schizophrenia and antipsychotic treatment]. Med Clin (Barc). 2012;139(12):542-6.10.1016/j.medcli.2012.05.02822841467
]Search in Google Scholar
[
40. Olfson M, Marcus SC, Corey-Lisle P, et al. Hyperlipidemia following treatment with antipsychotic medications. Am J Psychiatry 2006; 163:1821–1825.10.1176/ajp.2006.163.10.182117012695
]Search in Google Scholar
[
41. Raedler TJ. Cardiovascular aspects of antipsychotics. Curr Opin Psychiatry. 2010;23(6):574-81.10.1097/YCO.0b013e32833f46c920838345
]Search in Google Scholar
[
42. Brown S. Excess mortality of schizophrenia: a meta-analysis. Br J Psychiatry 1997; 171:502–508.10.1192/bjp.171.6.5029519087
]Search in Google Scholar
[
43. Ray WA, Chung CP, Murray KT, et al. Atypical antipsychotic drugs and the risk of sudden cardiac death. N Engl J Med 2009; 360:225–235.10.1056/NEJMoa0806994271372419144938
]Search in Google Scholar
[
44. Newcomer JW, Hennekens CH. Severe mental illness and risk of cardiovascular disease. JAMA 2007; 298:1794–1796.10.1001/jama.298.15.179417940236
]Search in Google Scholar
[
45. Newcomer JW. Antipsychotic medications: metabolic and cardiovascular risk. J Clin Psychiatry 2007; 68 (Suppl 4):8–13.10.4088/JCP.0507e13
]Search in Google Scholar
[
46. Halpert S, McFarlane SI. When the heart and the mind collide: cardiovascular risk factors and antipsychotic use in the schizophrenic population. J Cardiometab Syndr 2009; 4:1–5.10.1111/j.1559-4572.2008.00049.x19245509
]Search in Google Scholar
[
47. Harrigan EP, Miceli JJ, Anziano R, et al. A randomized evaluation of the effects of six antipsychotic agents on QTc, in the absence and presence of metabolic inhibition. J Clin Psychopharmacol 2004; 24:62–69.10.1097/01.jcp.0000104913.75206.6214709949
]Search in Google Scholar
[
48. Bresee LC, Majumdar SR, Patten SB, et al. Prevalence of cardiovascular risk factors and disease in people with schizophrenia: a population-based study. Schizophr Res 2010; 117:75–82.10.1016/j.schres.2009.12.01620080392
]Search in Google Scholar
[
49. Morissette P, Hreiche R, Mallet L, Vo D, Knaus EE, Turgeon J. Olanzapine prolongs cardiac repolarization by blocking the rapid component of the delayed rectifier potassium current. J Psychopharmacol. 2007;21(7):735-41.10.1177/026988110607266917092964
]Search in Google Scholar
[
50. Correll CU, Frederickson AM, Kane JM, et al. Metabolic syndrome and the risk of coronary heart disease in 367 patients treated with second-generation antipsychotic drugs. J Clin Psychiatry 2006; 67:575–583.10.4088/JCP.v67n0408
]Search in Google Scholar
[
51. Correll CU, Manu P, Olshanskiy V, et al. Cardiometabolic risk of secondgeneration antipsychotic medications during first-time use in children and adolescents. JAMA 2009; 302:1765–1773.10.1001/jama.2009.1549305579419861668
]Search in Google Scholar
[
52. Stöllberger C, Huber JO, Finsterer J. Antipsychotic drugs and QT prolongation. Int Clin Psychopharmacol. 2005;20(5):243-51.10.1097/01.yic.0000166405.49473.7016096514
]Search in Google Scholar
[
53. Czekalla J, Kollack-Walker S, Beasley CM Jr. Cardiac safety parameters of olanzapine: comparison with other atypical and typical antipsychotics. J Clin Psychiatry. 2001;62 Suppl 2:35-40.
]Search in Google Scholar
[
54. Puttegowda B, Theodore J, Basappa R, Nanjappa MC. Olanzapine Induced Dilated Cardiomyopathy. Malays J Med Sci. 2016;23(2):82-4.
]Search in Google Scholar
[
55. Belhani D, Frassati D, Mégard R, Tsibiribi P, Bui-Xuan B, Tabib A, Fanton L, Malicier D, Descotes J, Timour Q Exp Toxicol Pathol. 2006; 57(3):207-12.10.1016/j.etp.2005.09.00316410188
]Search in Google Scholar
[
56. Kataoka H, Kajiwara H, Yano E. Psychotropic drug-associated electrocardiographic presentation of diffuse J-waves in hypothermia: case report and literature review. Heart Vessels. 2016;31(6):996-1002.10.1007/s00380-015-0646-425666953
]Search in Google Scholar
[
57. Marder SR, Essock SM, Miller AL, et al. Physical health monitoring of patients with schizophrenia. Am J Psychiatry 2004; 161:1334–1349.10.1176/appi.ajp.161.8.133415285957
]Search in Google Scholar
[
58. Manu P, Dima L, Shulman M, Vancampfort D, De Hert M, Correll CU. Weight gain and obesity in schizophrenia: epidemiology, pathobiology, and management. Acta Psychiatr Scand. 2015;132(2):97-108.10.1111/acps.1244526016380
]Search in Google Scholar
[
59. A. Zuddas, R. Zanni, T. Usala, Second generation antipsychotics (SGAS) for non-psychotic disorders in children and adolescents: a review of the randomized controlled studies, Eur. Neuropsychopharmacol. 21 (2011) 600–620.10.1016/j.euroneuro.2011.04.00121550212
]Search in Google Scholar
[
60. D. Vancampfort, K. Vansteelandt, C.U. Correll, A.J. Mitchell, A. De Herdt, P. Sienaert, M. Probst, M. De Hert, Metabolic syndrome and metabolic abnormalities in bipolar disorder: a meta-analysis of prevalence rates and moderators, Am. J. Psychiatry 170 (2013) 265–274.
]Search in Google Scholar